

BIO-TECHNE CORP.

ISIN: US09073M1045

WKN: 09073M104

Asset Class: Stock

Company



2024/04/08 22:00:00

Price

68.22

USD

Difference



1.84%(1.23)



Contact Details

BIO-TECHNE CORP. Tel: +1-612-379-2956

-- Fax: +1-612-656-4400

McKinley Place NE 614 Web: <http://www.bio-techne.com>55413 Minneapolis E-mail: info@bio-techne.com

Company Profile

Financial figures, Fiscal year: from 01.07. to 30.06.

| Financial figures | 2023 | | 2022 | | 2021 | |
|--------------------------------|--------|------------------------|--------|------------------------|--------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | - | - | - | - | - | - |
| Common stock capital | - | - | - | - | - | - |
| Fixed assets | - | - | - | - | - | - |
| Equity capital of a company | - | - | - | - | - | - |
| Cash and cash equivalents | - | - | - | - | - | - |
| Accrued liabilities | - | - | - | - | - | - |
| Other assets | - | - | - | - | - | - |
| Current liabilities | - | - | - | - | - | - |
| Prepayments and accrued income | - | - | - | - | - | - |
| Non-current liabilities | - | - | - | - | - | - |
| Different income | - | - | - | - | - | - |
| Other liabilities | - | - | - | - | - | - |
| Total assets | - | - | - | - | - | - |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|--------|--------|--------|
| Accounting standard | - | - | - |
| Employees | - | - | - |
| Equity ratio | 71.94% | 71.71% | 67.22% |
| Debt-equity ratio | 39.01% | 39.45% | 48.77% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|-------|
| Tax Expense Rate | 15.71% | 12.70% | 5.80% |

BIO-TECHNE CORP.

ISIN: US09073M1045

WKN: 09073M104

Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Turnover | - | - | - |
| Net income | - | - | - |
| EBIT | 322,868,416 | 293,652,043 | 157,091,520 |
| Operating income before taxes | - | - | - |
| Cash Flow | - | - | - |
| Net interest income | - | - | - |
| Research and development expenses | - | - | - |
| Income taxes | - | - | - |
| Result from investments in subsidiaries, associates and other | - | - | - |
| Revenues per employee | 343,880 | 340,045 | 330,409 |

Board of Directors

Members of Management Board

| | |
|----------------------------------|--------------------------------|
| Robert Baumgartner | Chairman of Board of Directors |
| Alpna Seth | Member of Board of Directors |
| Joseph Keegan | Member of Board of Directors |
| Randolph Steer | Member of Board of Directors |
| Roeland Nusse | Member of Board of Directors |
| Rupert Vessey | Member of Board of Directors |
| John Higgins | Member of Board of Directors |
| Julie Bushman | Member of Board of Directors |
| Charles Kummeth (bis 30.06.2024) | Chairman of Managing Board |
| Brenda Furlow | Member of Executive Committee |
| David Eansor | Member of Executive Committee |
| Jim Hippel | Member of Executive Committee |
| Kim Kelderman | Member of Executive Committee |